Aegis Life, Inc. is a biotechnology company focused on developing innovative solutions to prevent and treat infectious diseases through nucleic acid-based vaccines and therapeutics. Central to their approach is the Fusogenix Proteolipid Vehicle (PLV) delivery platform, which has been refined over two decades of research in gene delivery. This platform addresses significant challenges in genetic medicine, particularly the effective delivery of genetic payloads into human cells. By combining the advantages of viral vector and lipid nanoparticle technologies, Fusogenix PLVs facilitate the direct delivery of various nucleic acid types, including mRNA, siRNA, and DNA, into target cells, demonstrating promising safety and efficacy in preclinical studies.

Aegis Life is actively advancing its pipeline of vaccine and therapeutic candidates aimed at combating both existing and emerging infectious diseases. Their development efforts include DNA-encoded therapeutic antibodies targeting diseases such as HIV and malaria, leveraging the unique properties of the Fusogenix PLV platform. This technology not only allows for the efficient production of these therapeutics but also ensures they are stable and cost-effective, making them accessible to populations in need, particularly in low- and middle-income countries. Aegis Life's commitment to rapid prototyping and scalable manufacturing positions them to respond effectively to public health challenges posed by infectious diseases.

United States

Aegis Life, Inc. is a biotechnology company founded in early 2020 with a mission to prevent and treat existing, emerging, and future contagions. Our nucleic acid delivery technology Fusogenix PLV stems from more than a decade of research and development in gene delivery. We actively leverage the Fusogenix PLV platform to accelerate the discovery, clinical development, and manufacture of vaccines and therapeutics for infectious diseases.

Aegis Life, Inc.

Company Details